knowledge -WSS

knowledge

author：Wikipedia 2025-08-25 07:28:35 - browse：1691

Moderna chairman Noubar Afeyan exuded star power earlier this month as he commanded the spotlight at BIO 2023, the industry’s largest convention.

Basking in the accolades heaped on Moderna’s celebrated Covid-19 vaccine, Afeyan regaled the Boston audience with the company’s origin story and greeted fans who lined up to snap selfies with him. Stuart Cable, a partner in the law firm Goodwin who’s represented Moderna and joined Afeyan on stage, called Moderna “arguably the most successful story in the history of biotechnology.”

But the Cambridge, Mass.-based company can’t afford to rest on its laurels. Two and a half years after its vaccine liberated tens of millions from pandemic lockdowns — ringing up more than $36 billion in sales so far — Moderna faces a changing business and regulatory environment. Demand for Covid shots is waning, a backlash over drug prices is gaining traction, and questions about its next act loom.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Why Charlie Gard's case is so disturbing to Americans

WSS

Medtronic CEO on promising devices for diabetes, hypertension

FDA authorizes Novavax’s updated Covid

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA has safety concerns on CRISPR

Chemotherapy drug shortage eases slightly but still widespread

Histogen: Failed biotech offers rare public look inside

leisure time

knowledge

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Emergency medicine has repudiated 'excited delirium.' Now what?

As demand for Covid shots wanes, Moderna seeks its next success

CDC recommends rationing of RSV shot due to shortages

Dobbs anniversary: the lost opportunity of abortion as health care

FDA panel signals lack of confidence in Amgen cancer drug data

Activists slam private health insurers over coverage restrictions

3 questions for the future of Biden's cancer moonshot

Guidelines to prevent youth baseball injuries need more muscle

Bristol 'take

leisure time

Hospitals warn Medicare's drug payment fix is ‘unlawful’

The future of health care in the House

AI can decode, harness the power of the humane immune system

FDA rejects Alnylam's heart disease treatment over insufficient data

Was Amgen transparent enough on FDA's concern on cancer drug?

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

focus

Wikipedia

hotspot

entertainment